Nymalize

May potentiate effects of anti-hypertensives (eg, diuretics, beta-blockers, ACEIs, ARBs, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, α-methyldopa; monitor and adjust dose if needed. Increased risk of hypotension with concomitant strong CYP3A4 inhibitors (eg, clarithromycin, telithromycin, indinavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir, ketoconazole, itraconazole, posaconazole, voriconazole, conivaptan, delaviridine, nefazodone): avoid. May be potentiated by moderate and weak CYP3A4 inhibitors (eg, alprazolam, amprenavir, amiodarone, aprepitant, atazanavir, cimetidine, cyclosporine, diltiazem, erythromycin, fluconazole, fluoxetine, isoniazid, oral contraceptives, quinupristin/dalfopristin, valproic acid, verapamil); monitor and reduce nimodipine dose may be needed. Avoid concomitant grapefruit juice. Antagonized by concomitant strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. Johns wort): avoid. May be antagonized by moderate and weak CYP3A4 inducers (eg, amprenavir, aprepitant, armodafinil, bosentan, efavirenz, etravirine, Echinacea, modafinil, nafcillin, pioglitazone, prednisone, rufinamide, and vemurafenib); monitor and increase nimodipine dose may be needed.